Acnatac® Gel left face — Competitive Intelligence Brief

Acnatac® Gel left face (Acnatac® Gel left face) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic combination. Area: Dermatology.

marketed Topical antibiotic combination Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide) Dermatology Small molecule

Target snapshot

Acnatac® Gel left face (Acnatac® Gel left face) — GWT-TUD GmbH. Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation on the skin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acnatac® Gel left face TARGET	Acnatac® Gel left face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide)
Duac Gel	Duac Gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination	Propionibacterium acnes (bacterial target); benzoyl peroxide acts via oxidative mechanism; clindamycin inhibits bacterial protein synthesis
Acnatac® Gel right face	Acnatac® Gel right face	GWT-TUD GmbH	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Clindamycin and BPO 5% gel	Clindamycin and BPO 5% gel	Stiefel, a GSK Company	marketed	Topical antibiotic combination with keratolytic agent	Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)
Duac® fixed dose combination gel	Duac® fixed dose combination gel	GlaxoSmithKline	marketed	Topical antibiotic combination	Bacterial ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Polysporin Triple	Polysporin Triple	University Health Network, Toronto	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic combination class)

1. Stiefel, a GSK Company · 3 drugs in this class
2. GlaxoSmithKline · 3 drugs in this class
3. GWT-TUD GmbH · 2 drugs in this class
4. Sun Pharmaceutical Industries, Inc. · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of British Columbia · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. B. Braun Medical SA · 1 drug in this class
9. Watson Laboratories, Inc. · 1 drug in this class
10. Padagis LLC · 1 drug in this class